- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2021 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Pediatrics
Guidelines for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic
June 23, 2021
The American College of Rheumatology has updated its treatment guidelines for the management of pediatric rheumatic disease during the COVID-19 pandemic. The guideline includes 33 final guidance recommendations, 8 of which received moderate-to-high task force consensus.
Genomic Risk Scores May Enhance JIA Diagnosis
October 05, 2020
In juvenile idiopathic arthritis, predictive genomic risk scores may enhance current diagnosis protocols, prioritizing higher-risk patients for follow-up and reducing treatment delays, according to a study published this month in Annals of Rheumatic Diseases.
Golimumab Approved for Pediatric Forms of Juvenile Arthritis and Psoriatic Arthritis
September 30, 2020
Golimumab (Simponi Aria, Janssen/J&J) has been approved by the U.S. Food and Drug Administration for two pediatric conditions:active pediatric juvenile idiopathic arthritis (JIA) and active pediatric psoriatic arthritis.
Image IQ: Infant with skin peeling
January 31, 2020
A 20-month-old boy with skin peeling, a strawberry red tongue and swelling of the hands and feet. Can you diagnose this patient?
FDA Approves First-Ever Treatment for Pediatric GPA, MPA
December 20, 2019
The U.S. Food and Drug Administration has approved rituximab (Rituxan, Genentech) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids, to fulfil an unmet medical need for these rare and serious diseases in children.
FDA Approves New Treatment for Rare Pediatric Vasculitis
October 01, 2019
The U.S. Food and Drug Administration has approved rituximab (Rituxan, Genentech) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids.
Nearly 5% of Children on Biologics Develop Hypersensitivity Reactions, Study Shows
August 22, 2019
Children with active rheumatic disease exposed to multiple biological drugs should be monitored for hypersensitivity reactions, particularly during intravenous infusions, say researchers writing in Pediatric Allergy and Immunology this month
FDA Rheumatology Drug Approvals: Pediatric lupus, spondyloarthritis and more
May 23, 2019
From a new biosimilar to a first-ever approved drug to treat pediatric lupus patients, the Food & Drug Administration has approved several new medications in recent months. In this slideshow, we offer a brief overview of these new therapeutics.
Vitamin D Supplementation During Pregnancy Makes Stronger Bones in Babies
March 11, 2019
Enhancing supplementation of vitamin D among pregnant women could have far-reaching implications on the bone health of whole societies. That was the conclusion drawn from a study conducted in Iran on the impact of low-dose vitamin D supplements on fetal bone development.